Literature DB >> 7037872

The treatment of severe Raynaud's phenomenon with verapamil.

E L Kinney, G G Nicholas, J Gallo, C Pontoriero, R Zelis.   

Abstract

Verapamil was evaluated in 16 patients with severe Raynaud's phenomenon. Fifty per cent of patients experienced subjective improvement by history, but only one patient had a substantial reduction in the frequency of Raynaud's phenomenon as assessed by diary analysis. We conclude that verapamil is not effective in most patients with severe Raynaud's phenomenon.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7037872     DOI： 10.1002/j.1552-4604.1982.tb05712.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


  14 in total

1.  Once daily felodipine in patients with primary Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; L Meems; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

3.  Managing Raynaud's phenomenon.

Authors:  S Roath
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-12

4.  Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.

Authors:  C Ferri; R Cecchetti; G Cini; I Gambini; L La Civita; L Bernini; S Bombardieri; G Pasero
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 5.  Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Authors:  K J Tietze; M L Schwartz; P H Vlasses
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

6.  The peripheral vascular effects of diltiazem--dose-response characteristics.

Authors:  M B Finch; G D Johnston
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

Review 7.  Drug treatment of scleroderma.

Authors:  C Leighton
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Management of Raynaud's phenomenon. Focus on newer treatments.

Authors:  S Roath
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 9.  Recent achievements in the management of Raynaud's phenomenon.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

10.  Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

Authors:  T Gjørup; O J Hartling; H Kelbaek; S L Nielsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.